Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SGB-OB08
- Development stage
- Preclinical
- Lead developer
- Sanegene Bio
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
SGB-OB08 is an investigational small interfering RNA (siRNA) therapeutic candidate being developed by SanegeneBio (Suzhou Shengyin Biopharmaceutical) for the treatment of obesity. The drug is engineered using SanegeneBio's proprietary LEAD™ (Ligand-conjugated Effective siRNA Delivery) platform, which utilizes GalNAc-like conjugation technology to facilitate the targeted delivery of siRNA to the liver. By leveraging the RNA interference (RNAi) pathway, SGB-OB08 aims to silence a specific, currently undisclosed gene target involved in metabolic regulation and energy homeostasis. As of 2024, the program is in the lead identification (Lead ID) stage of preclinical development, representing an early-stage effort to provide a long-acting, subcutaneous treatment option for weight management.
Beyond the preview
Go deeper on SGB-OB08.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SGB-OB08.